Switch theme
Sign up to access all valuation multiples
PT Pyridam Farma Tbk is an Indonesia-based company, engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through the following segments: Pharmaceutical Products and Toll Manufacturing Services; and Medical Device Products. The company derives maximum revenue from Pharmaceutical Products and Toll Manufacturing Services. The company's products include consumer health, Derma, prescription, and biomedilab.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pyridam Farma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Pyridam Farma achieved revenue of $42.2M and an EBITDA of $1.0M.
Pyridam Farma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pyridam Farma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $43.0M | $42.2M | XXX | XXX | XXX |
| Gross Profit | $14.7M | $15.1M | XXX | XXX | XXX |
| Gross Margin | 34% | 36% | XXX | XXX | XXX |
| EBITDA | $21.9M | $1.0M | XXX | XXX | XXX |
| EBITDA Margin | 51% | 2% | XXX | XXX | XXX |
| Net Profit | $0.3M | $16.5M | XXX | XXX | XXX |
| Net Margin | 1% | 39% | XXX | XXX | XXX |
| Net Debt | $23.3M | $45.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Pyridam Farma's stock price is IDR 181 (or $0).
Pyridam Farma has current market cap of IDR 2.03T (or $122M), and EV of IDR 5.41T (or $325M).
See Pyridam Farma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $325M | $122M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Pyridam Farma has market cap of $122M and EV of $325M.
Pyridam Farma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Pyridam Farma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pyridam Farma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $325M | XXX | XXX | XXX |
| EV/Revenue | 7.7x | XXX | XXX | XXX |
| EV/EBITDA | 339.5x | XXX | XXX | XXX |
| P/E | -23.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -42.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPyridam Farma's NTM/LTM revenue growth is n/a
Pyridam Farma's revenue per employee for the last fiscal year averaged $46K, while opex per employee averaged $20K for the same period.
Over next 12 months, Pyridam Farma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pyridam Farma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pyridam Farma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 2% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -96% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $46K | XXX | XXX | XXX | XXX |
| Opex per Employee | $20K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 43% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pyridam Farma acquired XXX companies to date.
Last acquisition by Pyridam Farma was XXXXXXXX, XXXXX XXXXX XXXXXX . Pyridam Farma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Pyridam Farma founded? | Pyridam Farma was founded in 1976. |
| Where is Pyridam Farma headquartered? | Pyridam Farma is headquartered in Indonesia. |
| How many employees does Pyridam Farma have? | As of today, Pyridam Farma has 921 employees. |
| Is Pyridam Farma publicy listed? | Yes, Pyridam Farma is a public company listed on IDX. |
| What is the stock symbol of Pyridam Farma? | Pyridam Farma trades under PYFA ticker. |
| When did Pyridam Farma go public? | Pyridam Farma went public in 2001. |
| Who are competitors of Pyridam Farma? | Similar companies to Pyridam Farma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pyridam Farma? | Pyridam Farma's current market cap is $122M |
| What is the current revenue growth of Pyridam Farma? | Pyridam Farma revenue growth between 2023 and 2024 was -2%. |
| Is Pyridam Farma profitable? | Yes, Pyridam Farma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
